Many reports suggest that there is a correlation between SRPK1 overexpression and higher tumor staging, grading, metastasis and shorter survival.4,5 Consequently, targeting SRPK1 has emerged as a promising therapeutic strategy. The gene discussed is SRPK1; the disease is neoplasm.